Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial Evaluating the Pharmacokinetics, Safety and Preliminary Efficacy of EP-104IAR (Long-Acting Fluticasone Propionate) in Patients With Osteoarthritis of the Knee
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Sep 2021
Price :
$35
*
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Osteoarthritis; Pain
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms STEPUP
- Sponsors Eupraxia Pharmaceuticals
- 16 Sep 2021 According to an Eupraxia Pharmaceuticals Media Release, results from this trial were published in Osteoarthritis and Cartilage Open.
- 16 Sep 2021 Results published in an Eupraxia Pharmaceuticals Media Release.
- 22 Jan 2018 Status changed from active, no longer recruiting to completed.